Dipyridyl amides: Potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 4, 2005, Pages 1197-1200

  Bonnefous, Céline ^a   Vernier, Jean Michel ^a   Hutchinson, John H ^a   Chung, Janice ^a   Reyes Manalo, Grace ^a   Kamenecka, Theodore ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Amides; CNS disorders; mGluR5

Indexed keywords

BIPYRIDINE DERIVATIVE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 16244380185     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.11.078     Document Type: Article

References (24)

1. S. Ozawa, H. Kamiya, and K. Tsuzuki Prog. Neurobiol. (Oxford) 54 1998 581
2. H. Brauener-Osborne, J. Egebjerg, E.O. Nielsen, U. Madsen, and P. Krogsgaard-Larsen J. Med. Chem. 43 2000 2609
3. J.-P. Pin, and F. Acher Curr. Drug Targets: CNS Neurol. Disord. 1 2002 297
4. P.J. Conn, and J.-P. Pin Annu. Rev. Pharmacol. Toxicol. 37 1997 205
5. M.A. Varney, and R.W.I. Gereau Curr. Drug Targets: CNS Neurol. Disord. 1 2002 283
6. J. Brodkin, C. Busse, S.J. Sukoff, and M.A. Varney Pharmacol., Biochem. Behav. 73 2002 359
7. W.P.J.M. Spooren, A. Vassout, H.C. Neijt, R. Kuhn, F. Gasparini, S. Roux, R.D. Porsolt, and C. Gentsch J. Pharmacol. Exp. Ther. 295 2000 1267
8. W.P.J.M. Spooren, P. Schoeffter, F. Gasparini, R. Kuhn, and C. Gentsch Eur. J. Pharmacol. 435 2002 161
9. E. Tatarczynska, A. Klodzinska, E. Chojnacka-Wojcik, A. Palucha, F. Gasparini, R. Kuhn, and A. Pilc Br. J. Pharmacol. 132 2001 1423
10. A. Klodzinska, E. Tatarczynska, E. Chojnacka-Wojcik, and A. Pilc Pol. J. Pharmacol. 52 2000 463
11. B. Schulz, M. Fendt, F. Gasparini, K. Lingenhohl, R. Kuhn, and M. Koch Neuropharmacology 41 2001 1
12. C. Chiamulera, M.P. Epping-Jordan, A. Zocchi, C. Marcon, C. Cottiny, S. Tacconi, M. Corsi, F. Orzi, and F. Conquet Nat. Neurosci. 4 2001 873
13. K.M. Huber, S.M. Gallagher, S.T. Warren, and M.F. Bear Proc. Nat. Acad. Sci. 99 2002 7746
14. Bradbury, M. J.; Cosford, N. D. P.; Varney, M. A.; Anderson, J. J., U.S. Patent 3,009,717, 2004
15. N.D.P. Cosford, L. Tehrani, J. Roppe, E. Schweiger, N.D. Smith, J. Anderson, L. Bristow, J. Brodkin, X. Jiang, I. McDonald, S.P. Rao, M. Washburn, and M.A. Varney J. Med. Chem. 46 2003 204
16. i (mGluR5) = 16 nM and 295 nM, respectively
17. Cragoe, E. J.; Bicking, J. B., Merck U.S. Patent 3,361,748, 1968
18. Using SmithCreator™ microwave from Personal Chemistry
19. Substitution and the 3-, 4-, and 5- position led to inactive compounds. 3- and 4-Pyridyl derivatives were also synthesized and were found to be inactive
20. 22-24
21. Despite rapid clearance in rats several compounds exhibited good to excellent receptor occupancy (ro). For example, compound 31: ro = 86% (iv dosing at 10 mg/kg)
22. M.A. Varney, N.D.P. Cosford, C. Jachec, S.P. Rao, A. Sacaan, F.-F. Lin, L. Bleicher, E.M. Santori, P.J. Flor, H. Allgeier, F. Gasparini, R. Kuhn, S.D. Hess, G. Veliçelebi, and E.C. Johnson J. Pharmacol. Exp. Ther. 290 1999 170
23. M.A. Varney, and C.M. Suto Drug Discovery Today: HTS Suppl. 1 2000 20
24. L.P. Daggett, A.I. Sacaan, M. Akong, S.P. Rao, S.D. Hess, C. Liaw, A. Urrutia, C. Jachec, S.B. Ellis, J. Dressen, T. Knöpfel, G.B. Landwehrmeyer, and G. Veliçelebi Neuropharmacology 34 1995 871